The FDA is investigating the death last month of an eight-year-old boy in Brazil who had received Sarepta Therapeutics’ Elevidys® (delandistrogene moxeparvovec-rokl)—though the company and its ...

Barclays downgraded Sarepta (SRPT) to Underweight from Equal Weight with a price target of $10, down from $18. The firm says the suspension of ...

The Fed is expected to keep rates steady, but Powell will get questions on Fed independence. Apple, Microsoft, Meta and ...

The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...